However, data from the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) clinical study indicated that MR antagonists may be related to an increased risk for the development of diabetes [67]. This evidence concerns the gene NR3C2 and heart failure.